Evidence map›Paper›PMID 33261050›Full record

ReviewGenes2020

Properties and Therapeutic Implications of an Enigmatic D477G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa.

Anna-Sophia Kiang, Paul F Kenna, Marian M Humphries, Ema Ozaki, Robert K Koenekoop, Matthew Campbell, G Jane Farrar, Pete Humphries

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Dynamic Inner Blood Retina Barrier Disruption in Retinitis Pigmentosa.Investigative ophthalmology & visual science · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Choroideremia: Toward Regulatory Approval of Retinal Gene Therapy.Cold Spring Harbor perspectives in medicine · 2023
    Article
  7. Article
  8. Genetic dissection of non-syndromic retinitis pigmentosa.Indian journal of ophthalmology · 2022
    Review
  9. Retinal pigment epithelium 65 kDa protein (RPE65): An update.Progress in retinal and eye research · 2022
    Review
  10. The interplay of environmental luminance and genetics in the retinal dystrophy induced by the dominant RPE65 mutation.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Anna-Sophia KiangThe School of Genetics & Microbiology, Trinity College Dublin, D02 VF25 Dublin, Ireland.
Paul F KennaThe School of Genetics & Microbiology, Trinity College Dublin, D02 VF25 Dublin, Ireland.
Marian M HumphriesThe School of Genetics & Microbiology, Trinity College Dublin, D02 VF25 Dublin, Ireland.
Ema OzakiDepartment of Clinical Medicine, School of Medicine, Trinity College Dublin, 2 D02 R590 Dublin, Ireland.
Robert K KoenekoopDepartments of Ophthalmology, Human Genetics and Paediatric Surgery, Montreal Children's Hospital, McGill University Health Centre, McGill University, Montreal, QC H3A 0G4, Canada.
Matthew CampbellThe School of Genetics & Microbiology, Trinity College Dublin, D02 VF25 Dublin, Ireland.
G Jane FarrarThe School of Genetics & Microbiology, Trinity College Dublin, D02 VF25 Dublin, Ireland.
Pete HumphriesThe School of Genetics & Microbiology, Trinity College Dublin, D02 VF25 Dublin, Ireland.
Trinity College Dublin · IEMontreal Children's Hospital · CARoyal Victoria Eye and Ear Hospital · IE

Funding

CIHR
6 · The paper itself

Abstract

RPE65 isomerase, expressed in the retinal pigmented epithelium (RPE), is an enzymatic component of the retinoid cycle, converting all-trans retinyl ester into 11-cis retinol, and it is essential for vision, because it replenishes the photon capturing 11-cis retinal. To date, almost 200 loss-of-function mutations have been identified within the

Indexed as

Amino Acid SubstitutionGenes, DominantMutation, MissensePoint MutationAge of OnsetAnimalsChoroideremiacis-trans-IsomerasesClinical Trials, Phase I as TopicDNA, ComplementaryEnzyme Replacement TherapyFemaleGene Knock-In TechniquesGenetic TherapyGenetic VectorsHumanscis-trans-IsomerasesDNA, ComplementaryProtein IsoformsRetinaldehydeRetinoid Isomerohydrolase9-cis retinaldehydeautosomal dominant retinitis pigmentosaincomplete penetranceknock-in mouse modelsRPE65

Identifiers

PMID33261050
PMCPMC7760593
OpenAlexW3109832430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.